Menu

Novartis

Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL

, , , ,

Analysis of 75 patients with median follow-up of more than a year demonstrated an overall remission rate of 81% Event-free survival and overall survival at six months were 73% and 90%, with median duration of remission not reached Kymriah was detected in patients up to 20 months, demonstrating long-term persistence Novartis is committed to bringing […]

GSK completes divestment of rights to ofatumumab for auto-immune indications to Novartis

, , , ,

21 December 2015, London – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the completion of its transaction to divest its rights to ofatumumab for auto-immune indications to Novartis Pharma AG (“Novartis Pharma”), a subsidiary of Novartis AG, following regulatory approval. The consideration payable by Novartis Pharma to GSK may reach up to $1,034 million and comprises a series […]

300 million child-friendly antimalarial treatments supplied without profit by Novartis

, , ,

Coartem® Dispersible*, the first WHO prequalified[1] pediatric antimalarial treatment, has become the standard of care in over 30 malaria-endemic countries Since 2009, Novartis has supplied 300 million Coartem® Dispersible treatments without profit, mostly to the public sector, to treat children suffering from malaria Together with other innovations, Coartem® Dispersible contributed to reduce the malaria death […]